[Monoclonal antibody UW 21/123: clinical use and diagnostic specificity in head and neck cancers].
In addition to the originally described monoclonal antibody (MAB) against laryngeal carcinoma cells (Arch. Otorhinolaryngol. 233 (1981) 161) a new MAB was induced by means of somatic cell hybridisation techniques. The MAB UW 21/123 enables recognition of a group of squamous cell carcinomas of the head and neck. An in-vitro assay was designed allowing clinical diagnosis of malignancy in 18% out of 211 tumour patients.
D000911:Antibodies, Monoclonal / Q000276:immunology; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology; D003528:Carcinoma, Adenoid Cystic / Q000175:diagnosis; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis; D002460:Cell Line; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000175:diagnosis; D007822:Laryngeal Neoplasms / Q000175:diagnosis; D008545:Melanoma / Q000175:diagnosis; D009959:Oropharyngeal Neoplasms / Q000175:diagnosis; D010212:Papilloma / Q000175:diagnosis; D014062:Tongue Neoplasms / Q000175:diagnosis
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm
Der monoklonale Antikörper UW 21/123: Klinische Anwendung und diagnostische Spezifität bei Kopf- und Halskarzinomen.